Now showing items 1-2 of 2

    • Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease 

      Fernández-Laso, V.; Méndez-Barbero, N.; Valdivielso Revilla, José Manuel; Betriu i Bars, M. Àngels; Fernández i Giráldez, Elvira; Egido, Jesús; Martín-Ventura, JL.; Blanco-Colio, LM. (Elsevier, 2017-03-31)
      BACKGROUND AND AIMS: Circulating soluble TNF-like weak inducer of apoptosis (sTWEAK) concentrations are related to the presence of chronic kidney disease (CKD) and cardiovascular disease (CVD). However, there are no data ...
    • Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD 

      Fernández-Laso, V.; Sastre, Cristina; Valdivielso Revilla, José Manuel; Betriu i Bars, M. Àngels; Fernández i Giráldez, Elvira; Egido, Jesús; Martín-Ventura, JL.; Blanco-Colio, LM. (American Society of Nephrology, 2016-03)
      Abstract BACKGROUND AND OBJECTIVES: Soluble TNF-like weak inducer of apoptosis (sTWEAK) is a proinflammatory cytokine belonging to the TNF superfamily. sTWEAK concentrations have been associated with the presence of CKD ...